Certara (NasdaqGS:CERT) FY Conference Transcript

Summary of Certara FY Conference Call (March 10, 2026) Company Overview - Company: Certara (NasdaqGS:CERT) - Industry: Life Science Tools and Diagnostics Key Financial Performance - Revenue: Organic software revenue for FY 2025 was 7%, within the guidance range of 6%-8% [5] - EBITDA Margin: Achieved 32%, exceeding the guidance of 30%-32% [5] - Bookings: Mixed performance in Q4; December saw a strong 17% increase in services bookings [6][7] - Software Bookings: Trailing twelve-month organic software bookings were only 1%, indicating a decline year-on-year in Q4 [7][8] Market Dynamics - Customer Behavior: Notable reduction in seat licenses from tier one customers due to headcount reductions in Big Pharma [14][15] - Study Counts: Decreased clinical trial starts 18-24 months prior affected software bookings, particularly for the Pinnacle 21 platform [15][16] - Seasonality: Q4 showed strong discretionary spending, but services bookings remain lumpy historically [6][7] 2026 Guidance and Expectations - Revenue Growth: Expected to be flat to up 4% for 2026, with Q1 anticipated to be on the lower end of the guidance range [8][20] - New Product Launches: Three new software products launched in Q4, including Certara IQ for QSP and Phoenix Cloud, expected to drive growth [22][30] Product Development and AI Integration - Certara IQ: AI-enabled software for quantitative systems pharmacology (QSP), aimed at enhancing internal project throughput and customer sales [28][30] - Phoenix Cloud: Cloud version of the Phoenix platform, designed to transition customers from desktop to cloud, with positive initial reception [32][35] - AI as Competitive Advantage: Integration of AI technology from Vyasa is seen as a unique opportunity to enhance software offerings and maintain customer reliance [42][44] Regulatory Services and Strategic Evaluation - Regulatory Writing Business: High profit margins (20%-30%) but facing revenue declines; under evaluation for potential sale or retention [58][61] - CEO's Focus: New CEO Jon Resnick is assessing the regulatory business's status and its impact on shareholder value [55][57] Investment and Growth Strategy - Customer-Centric Approach: Emphasis on unifying software and services to better meet customer needs and enhance value proposition [72][73] - Rule of Forty: Company aims to align with the rule of forty, currently slightly below due to investments impacting margins [79][80] - Cost Management: Identified $10 million in cost avoidance opportunities while maintaining disciplined spending [83][85] Conclusion - Certara is navigating a transitional phase with mixed financial performance, focusing on new product launches and AI integration to drive future growth while evaluating its regulatory services segment for strategic decisions.